Chronic obstructive pulmonary disease (COPD) is a common and disabling disease and the
third leading cause of global mortality behind ischemic heart disease and stroke. Acute exacerbations
of COPD accelerate lung function decline affecting the quality of life of COPD patients and moreover,
remain the major contributors to morbidity and mortality of these patients. Cardiovascular comorbidities
are prevalent in COPD patients and of great importance since they have a negative impact on patients’
health status. During the past few years there is an increasing interest in potential molecules that
can be measured accurately and reproducibly and that can be used in COPD as biomarkers to predict
clinical important outcomes such as exacerbations, hospitalizations and mortality. Such molecules
have been successfully used in cardiovascular diseases and therefore, cardiac biomarkers have attracted attention for their
potential use in COPD. The present review summarizes the available evidence for the use of the most important cardiac
biomarkers in the evaluation of COPD severity, outcomes and management.
Keywords: Cardiac biomarkers, Chronic obstructive pulmonary disease, Acute exacerbations of chronic obstructive pulmonary
disease, Comorbidities, Copeptin, B-natriuretic peptide, Adrenomedullin, Troponin T.
Rights & PermissionsPrintExport